Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


"Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment".

Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L.

Cancer Lett. 2018 Sep 18. pii: S0304-3835(18)30580-9. doi: 10.1016/j.canlet.2018.09.023. [Epub ahead of print]


Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.


Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K.

Oncotarget. 2017 Aug 12;8(44):76921-76934. doi: 10.18632/oncotarget.20217. eCollection 2017 Sep 29.


Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.

Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM.

Mol Oncol. 2017 Oct;11(10):1361-1379. doi: 10.1002/1878-0261.12105. Epub 2017 Jul 24.


The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O.

Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9.


Fatigue During and After Breast Cancer Therapy-A Prospective Study.

Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE.

J Pain Symptom Manage. 2017 Mar;53(3):551-560. doi: 10.1016/j.jpainsymman.2016.09.011. Epub 2016 Dec 29.


Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts.

Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E.

Mol Imaging Biol. 2017 Apr;19(2):271-279. doi: 10.1007/s11307-016-0998-x.


Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S.

Br J Cancer. 2015 Dec 1;113(11):1548-55. doi: 10.1038/bjc.2015.380. Epub 2015 Nov 10.


Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C.

Genes Dev. 2015 Jun 15;29(12):1298-315. doi: 10.1101/gad.263202.115. Epub 2015 Jun 16.


Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft.

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K.

PLoS One. 2014 Nov 24;9(11):e113278. doi: 10.1371/journal.pone.0113278. eCollection 2014.


Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts.

Kristian A, Riss P, Qu H, Milde M, Schoultz BW, Engebraaten O, Mælandsmo GM, Malinen E.

Acta Oncol. 2014 Aug;53(8):1086-92. doi: 10.3109/0284186X.2014.934398. Epub 2014 Jul 14.


Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis.

Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T.

J Magn Reson Imaging. 2014 Dec;40(6):1382-91. doi: 10.1002/jmri.24502. Epub 2014 Jan 27.


Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS.

Breast Cancer Res. 2014 Jan 21;16(1):R5. doi: 10.1186/bcr3597.


Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O.

Clin Cancer Res. 2014 Jan 15;20(2):404-12. doi: 10.1158/1078-0432.CCR-13-1865. Epub 2013 Nov 5.


Triple-negative breast cancer and the need for new therapeutic targets.

Engebraaten O, Vollan HKM, Børresen-Dale AL.

Am J Pathol. 2013 Oct;183(4):1064-1074. doi: 10.1016/j.ajpath.2013.05.033. Epub 2013 Aug 3. Review.


Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS.

J Magn Reson Imaging. 2013 Nov;38(5):1043-53. doi: 10.1002/jmri.24079. Epub 2013 Mar 21.


Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.

Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T.

Mol Oncol. 2013 Feb;7(1):130-42. doi: 10.1016/j.molonc.2012.10.005. Epub 2012 Oct 23.


Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.

Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM.

PLoS One. 2012;7(9):e45492. doi: 10.1371/journal.pone.0045492. Epub 2012 Sep 20.


Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V.

ISRN Oncol. 2012;2012:176789. doi: 10.5402/2012/176789. Epub 2012 May 14.


Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.

Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O.

Mol Oncol. 2012 Aug;6(4):418-27. doi: 10.1016/j.molonc.2012.03.006. Epub 2012 Mar 31.


In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.

Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Krüger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS.

J Magn Reson Imaging. 2012 May;35(5):1098-107. doi: 10.1002/jmri.23507. Epub 2011 Dec 14.


Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Moestue SA, Engebraaten O, Gribbestad IS.

Mol Oncol. 2011 Jun;5(3):224-41. doi: 10.1016/j.molonc.2011.04.001. Epub 2011 Apr 23. Review.


13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns.

Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS.

NMR Biomed. 2011 Dec;24(10):1243-52. doi: 10.1002/nbm.1683. Epub 2011 Apr 4.


Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.

Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T.

Eur Radiol. 2011 Jun;21(6):1188-99. doi: 10.1007/s00330-010-2020-3. Epub 2010 Dec 3.


Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.

Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS.

BMC Cancer. 2010 Aug 17;10:433. doi: 10.1186/1471-2407-10-433.


Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.

Andersson Y, Engebraaten O, Fodstad Ø.

Br J Cancer. 2009 Oct 20;101(8):1307-15. doi: 10.1038/sj.bjc.6605312. Epub 2009 Sep 22.


Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models.

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O.

Mol Oncol. 2009 Dec;3(5-6):469-82. doi: 10.1016/j.molonc.2009.07.003. Epub 2009 Aug 4.


Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins.

Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad Ø.

Anticancer Res. 2009 Jan;29(1):131-7.


Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.

Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O.

J Gene Med. 2007 Jun;9(6):440-51.


Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines.

Engesaeter BØ, Bonsted A, Lillehammer T, Engebraaten O, Berg K, Maelandsmo GM.

Cancer Biol Ther. 2006 Nov;5(11):1511-20. Epub 2006 Nov 19.


Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus.

Engesaeter BØ, Tveito S, Bonsted A, Engebraaten O, Berg K, Maelandsmo GM.

J Gene Med. 2006 Jun;8(6):707-18.


Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.

Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O.

Cancer Gene Ther. 2005 Nov;12(11):864-72.


Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells.

Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad Ø, Engebraaten O.

Exp Cell Res. 2004 Mar 10;294(1):130-9.


Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1.

Hjortland GO, Bjørnland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesland JM, Fodstad O, Engebraaten O.

Clin Exp Metastasis. 2003;20(4):301-9.


Expression of extracellular matrix components in a highly infiltrative in vivo glioma model.

Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, Engebraaten O.

Acta Neuropathol. 2003 Jan;105(1):49-57. Epub 2002 Nov 1.


Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals.

Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O.

Int J Cancer. 2002 Feb 20;97(6):846-52.


Invasiveness in vitro and biological markers in human primary glioblastomas.

Laerum OD, Nygaar SJ, Steine S, Mørk SJ, Engebraaten O, Peraud A, Kleihues P, Ohgaki H.

J Neurooncol. 2001 Aug;54(1):1-8.


Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats.

Engebraaten O, Sivam G, Juell S, Fodstad O.

Int J Cancer. 2000 Dec 15;88(6):970-6.


Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells.

Suzuki T, Anderegg B, Ohkawa T, Irie A, Engebraaten O, Halks-Miller M, Holm PS, Curiel DT, Kashani-Sabet M, Scanlon KJ.

Gene Ther. 2000 Feb;7(3):241-8.


lacZ-neoR transfected glioma cells in syngeneic rats: growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS.

Visted T, Thorsen J, Thorsen F, Read TA, Ulvestad E, Engebraaten O, Sorensen D, Ylä-Herttuala S, Tyynela K, Rucklidge G, Edvardsen K, Bjerkvig R, Lund-Johansen M.

Int J Cancer. 2000 Jan 15;85(2):228-35.


Expression of a novel factor in human breast cancer cells with metastatic potential.

Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O.

Cancer Res. 1999 Sep 15;59(18):4675-80.


Growth of precultured human glioma specimens in nude rat brain.

Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O.

J Neurosurg. 1999 Jan;90(1):125-32.


Role of high molecular weight extracellular matrix proteins in glioma cell migration.

Mahesparan R, Tysnes BB, Edvardsen K, Haugeland HK, Cabrera IG, Lund-Johansen M, Engebraaten O, Bjerkvig R.

Neuropathol Appl Neurobiol. 1997 Apr;23(2):102-12.


Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O.

Cancer Res. 1996 Dec 1;56(23):5490-8.


Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.

Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O.

Br J Cancer. 1996 Apr;73(8):909-16.


Leptomeningeal tissue: a barrier against brain tumor cell invasion.

Pedersen PH, Rucklidge GJ, Mørk SJ, Terzis AJ, Engebraaten O, Lund-Johansen M, Backlund EO, Laerum OD, Bjerkvig R.

J Natl Cancer Inst. 1994 Nov 2;86(21):1593-9.


Organ culture of a glioblastoma from a patient with an unusually long survival.

Wester K, Bjerkvig R, Cressey L, Engebraaten O, Mørk S.

Neurosurgery. 1994 Sep;35(3):428-32; discussion 432-3.


Supplemental Content

Loading ...
Support Center